Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACH

Respiratory Research

Helmut Ostermann³  Kyle McBride⁶  Marco Ávila²  Jesús Medina⁴  Javier Garau⁵  Francesco Blasi¹ 

[1] Department of Pathophysiology and Transplantation, Università degli Studi di Milano, IRCCS Fondazione Ca’ Granda, Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122, Milan, Italy;AstraZeneca EMEA, Level 7, 2 Kingdom Street, London, W2 6BD, UK;Department of Internal Medicine III, Haematology and Oncology, University Hospital Munich, Munich, Germany;Medical Evidence Centre (Global Medical Affairs), AstraZeneca, Parque Norte, Edificio Roble, Serrano Galvache 56, Madrid, 28033, Spain;Department of Medicine, Hospital Universitari Mutua de Terrassa, Plaza Doctor Robert 5, Terrassa, Barcelona, 08221, Spain;Instat Services, Inc., 1 Wilson Street, Chatham, NJ, 07928, USA

关键词: Retrospective studies;    Community-acquired pneumonia;    Clinical management;    Antibacterial agents;   

Others  :  794746
DOI  :  10.1186/1465-9921-14-44

 received in 2012-12-22, accepted in 2013-04-04,  发布年份 2013

【 摘 要 】

Background

Data describing real-life management and treatment of community-acquired pneumonia (CAP) in Europe are limited. REACH (http://NCT01293435 webcite) was a retrospective, observational study collecting data on the management of EU patients hospitalized with CAP.

The purpose of this study was to understand patient and disease characteristics in patients hospitalized with CAP and to review current clinical practices and outcomes.

Methods

Patients were aged ≥18 years, hospitalized with CAP between March 2010 and February 2011, and requiring in-hospital treatment with intravenous antibiotics. An electronic Case Report Form was used to collect patient, disease and treatment variables, including type of CAP, medical history, treatment setting, antibiotics administered and clinical outcomes.

Results

Patients (N = 2,039) were recruited from 128 centres in ten EU countries (Belgium, France, Germany, Greece, Italy, the Netherlands, Portugal, Spain, Turkey, UK). The majority of patients were aged ≥65 years (56.4%) and had CAP only (78.8%). Initial antibiotic treatment modification occurred in 28.9% of patients and was more likely in certain groups (patients with comorbidities; more severely ill patients; patients with healthcare-associated pneumonia, immunosuppression or recurrent episodes of CAP). Streamlining (de-escalation) of therapy occurred in 5.1% of patients. Mean length of hospital stay was 12.6 days and overall mortality was 7.2%.

Conclusion

These data provide a current overview of clinical practice in patients with CAP in EU hospitals, revealing high rates of initial antibiotic treatment modification. The findings may precipitate reassessment of optimal management regimens for hospitalized CAP patients.

【 授权许可】

   
2013 Blasi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Woodhead M: Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J Suppl 2002, 36:20s-27s.
• [2]Welte T: Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality. Eur J Clin Microbiol Infect Dis 2012, 31:33-47.
• [3]Welte T, Kohnlein T: Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. Semin Respir Crit Care Med 2009, 30:127-135.
• [4]Capelastegui A, Espana PP, Bilbao A, Gamazo J, Medel F, Salgado J, Gorostiaga I, Esteban C, Altube L, Gorordo I, Quintana JM: Study of community-acquired pneumonia: incidence, patterns of care, and outcomes in primary and hospital care. J Infect 2010, 61:364-371.
• [5]Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Read R, Verheij TJ: Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect 2011, 17(Suppl 6):E1-E59.
• [6]Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-S72.
• [7]Martinez R, Reyes S, Lorenzo MJ, Menendez R: Impact of guidelines on outcome: the evidence. Semin Respir Crit Care Med 2009, 30:172-178.
• [8]BTS guidelines for the management of community acquired pneumonia in adults Thorax 2001, 56(Suppl 4):IV1-IV64.
• [9]Welte T, Torres A, Nathwani D: Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2010, 67:71-79.
• [10]Aspa J, Rajas O, de Castro FR: Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia. Expert Opin Pharmacother 2008, 9:229-241.
• [11]Bauer TT, Welte T, Ernen C, Schlosser BM, Thate-Waschke I, de Zeeuw J, Schultze-Werninghaus G: Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 2005, 128:2238-2246.
• [12]World Health Organization: International Classification of Diseases (ICD) 10th Revision (2007 version). Geneva, Switzerland: World Health Organization; 2007.
• [13]Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250.
• [14]Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58:377-382.
• [15]Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS, Singer DE: Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998, 279:1452-1457.
• [16]Ramirez JA, Anzueto AR: Changing needs of community-acquired pneumonia. J Antimicrob Chemother 2011, 66(Suppl 3):iii3-iii9.
• [17]Garau J, Baquero F, Perez-Trallero E, Perez JL, Martin-Sanchez AM, Garcia-Rey C, Martin-Herrero JE, Dal-Ré R: Factors impacting on length of stay and mortality of community-acquired pneumonia. Clin Microbiol Infect 2008, 14:322-329.
• [18]Blasi F, Iori I, Bulfoni A, Corrao S, Costantino S, Legnani D: Can CAP guideline adherence improve patient outcome in internal medicine departments? Eur Respir J 2008, 32:902-910.
• [19]Garcia-Vidal C, Carratala J: Early and late treatment failure in community-acquired pneumonia. Semin Respir Crit Care Med 2009, 30:154-160.
• [20]Stralin K, Olcen P, Tornqvist E, Holmberg H: Definite, probable, and possible bacterial aetiologies of community-acquired pneumonia at different CRB-65 scores. Scand J Infect Dis 2010, 42:426-434.
• [21]Garcia-Vidal C, Carratala J, Fernandez-Sabe N, Dorca J, Verdaguer R, Manresa F, Gudiol F: Aetiology of, and risk factors for, recurrent community-acquired pneumonia. Clin Microbiol Infect 2009, 15:1033-1038.
• [22]Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Raga-Luria X, Gomez-Bertomeu F: Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir Med 2009, 103:309-316.
• [23]Gutierrez F, Masia M, Rodriguez JC, Mirete C, Soldan B, Padilla S, Hernandez I, De Ory F, Royo G, Hidalgo AM: Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain. Clin Microbiol Infect 2005, 11:788-800.
• [24]Hedlund J, Ortqvist A, Ahlqvist T, Augustinsson A, Beckman H, Blanck C, Burman LA, Claesson B, Qvarfordt I, Elbel E, Erntell M, Follin P, Goscinski G, Holmberg H, Hofer M, Jorup C, Lidman C, Lindhusen E, Rensfeldt G, Rosenkvist E, Stenlund G, Stalberg A, Verngren K, Vig I, Wendahl S: Management of patients with community-acquired pneumonia treated in hospital in Sweden. Scand J Infect Dis 2002, 34:887-892.
• [25]Valencia M, Badia JR, Cavalcanti M, Ferrer M, Agusti C, Angrill J, Garcia E, Mensa J, Niederman MS, Torres A: Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest 2007, 132:515-522.
• [26]Tudose C, Bumbacea D, Bogdan M: Antibiotic resistance of S. pneumoniae and H. influenzae strains isolated from patients with community acquired respiratory tract infections. BACTRO multicenter, multidisciplinary study. Pneumologia 2011, 60:30-35.
• [27]Valles X, Marcos A, Pinart M, Piner R, Marco F, Mensa JM, Torres A: Hospitalized community-acquired pneumonia due to Streptococcus pneumoniae: Has resistance to antibiotics decreased? Chest 2006, 130:800-806.
• [28]Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163:1730-1754.
• [29]Dambrava PG, Torres A, Valles X, Mensa J, Marcos MA, Penarroja G, Camps M, Estruch R, Sanchez M, Menendez R, Niederman MS: Adherence to guidelines' empirical antibiotic recommendations and community-acquired pneumonia outcome. Eur Respir J 2008, 32:892-901.
• [30]Orrick JJ, Segal R, Johns TE, Russell W, Wang F, Yin DD: Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to infectious diseases society of america guidelines. Pharmacoeconomics 2004, 22:751-757.
• [31]Merchant S, Mullins CD, Shih YC: Factors associated with hospitalization costs for patients with community-acquired pneumonia. Clin Ther 2003, 25:593-610.
• [32]Brown PD: Adherence to guidelines for community-acquired pneumonia: does it decrease cost of care? Pharmacoeconomics 2004, 22:413-420.